These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2890425)

  • 1. Anatomy and pathology of the basal ganglia.
    McGeer PL; McGeer EG; Itagaki S; Mizukawa K
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):363-72. PubMed ID: 2890425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia.
    Palacios JM; Chinaglia G; Rigo M; Ulrich J; Probst A
    Synapse; 1991 Feb; 7(2):114-22. PubMed ID: 1672780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-basal ganglia antibody].
    Hayashi M
    Brain Nerve; 2013 Apr; 65(4):377-84. PubMed ID: 23568985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anatomy and pathology of extrapyramidal diseases.
    Seab JA
    Brain Res Bull; 1983 Aug; 11(2):135-41. PubMed ID: 6226338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.
    Dale RC; Merheb V; Pillai S; Wang D; Cantrill L; Murphy TK; Ben-Pazi H; Varadkar S; Aumann TD; Horne MK; Church AJ; Fath T; Brilot F
    Brain; 2012 Nov; 135(Pt 11):3453-68. PubMed ID: 23065479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study.
    Waeber C; Palacios JM
    Neuroscience; 1989; 32(2):337-47. PubMed ID: 2531301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotransmitters and neurodegenerative disorders.
    Kanazawa I
    Clin Ther; 1984; 7 Spec No():48-58. PubMed ID: 6152198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The thalamostriatal system: a highly specific network of the basal ganglia circuitry.
    Smith Y; Raju DV; Pare JF; Sidibe M
    Trends Neurosci; 2004 Sep; 27(9):520-7. PubMed ID: 15331233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric complications of some basal-ganglia disorders.
    Whitlock FA
    Br J Hosp Med; 1988 Nov; 40(5):391, 394-5. PubMed ID: 3069174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional anatomy of thalamus and basal ganglia.
    Herrero MT; Barcia C; Navarro JM
    Childs Nerv Syst; 2002 Aug; 18(8):386-404. PubMed ID: 12192499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal ganglia: anatomy, pathology, and imaging characteristics.
    Anderson JC; Costantino MM; Stratford T
    Curr Probl Diagn Radiol; 2004; 33(1):28-41. PubMed ID: 14712200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sydenham's chorea: magnetic resonance imaging of the basal ganglia.
    Giedd JN; Rapoport JL; Kruesi MJ; Parker C; Schapiro MB; Allen AJ; Leonard HL; Kaysen D; Dickstein DP; Marsh WL
    Neurology; 1995 Dec; 45(12):2199-202. PubMed ID: 8848193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anatomical and biochemical basis of the extrapyramidal disorders.
    Gauthier S; Sourkes TL
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):595-9. PubMed ID: 6131493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification.
    Chakrabarty P; Ceballos-Diaz C; Lin WL; Beccard A; Jansen-West K; McFarland NR; Janus C; Dickson D; Das P; Golde TE
    Nat Neurosci; 2011 Jun; 14(6):694-6. PubMed ID: 21572432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal ganglia: functional anatomy and physiology. Part 2.
    Afifi AK
    J Child Neurol; 1994 Oct; 9(4):352-61. PubMed ID: 7822723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.
    Buck SH; Burks TF; Brown MR; Yamamura HI
    Brain Res; 1981 Mar; 209(2):464-9. PubMed ID: 6164436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal ganglia: functional anatomy and physiology. Part 1.
    Afifi AK
    J Child Neurol; 1994 Jul; 9(3):249-60. PubMed ID: 7930403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.